A Study of CC-99712 a BCMA Antibody-Drug Conjugate in Subjects With Relapsed and Refractory Multiple Myeloma

  • End date
    May 27, 2025
  • participants needed
  • sponsor
Updated on 27 February 2021
Associate Director Clinical Trial Disclosure
Primary Contact
Florida Cancer Specialists (5.4 mi away) Contact
+9 other location
measurable disease
neutrophil count
proteasome inhibitor
refractory multiple myeloma
immunotherapeutic agent


Study CC-99712-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical study of CC-99712 in subjects with relapsed and refractory multiple myeloma (MM). The dose escalation part (Part A) of the study will evaluate the safety and tolerability of escalating doses of CC-99712, administered intravenously (IV), to determine the maximum tolerated dose (MTD) and non-tolerated dose (NTD) of CC-99712 using a modified accelerated titration design and Bayesian methodology. The MTD and NTD may be established separately for CC-99712 administered at Q3W and/ or Q4W schedules. The expansion part (Part B) will further evaluate the safety and efficacy of CC-99712 administered at or below the MTD in selected expansion cohorts in order to determine the RP2D. One or more dosing regimens may be selected for cohort expansion. All subjects will be treated until confirmed disease progression per IMWG criteria, unacceptable toxicity, or subject/Investigator decision to withdraw.

Condition Multiple Myeloma, Lymphoproliferative Disorder, Lymphoproliferative disorders, multiple myeloma (mm)
Treatment CC-99712
Clinical Study IdentifierNCT04036461
Last Modified on27 February 2021


Yes No Not Sure

Inclusion Criteria

Subjects must satisfy the following criteria to be enrolled in the study
Subject (male or female) is 18 years of age at the time of signing the ICF
Subject has a history of MM with relapsed and refractory disease, and must
Have disease that is nonresponsive while on their last antimyeloma therapy or documented disease progression on or within 60 days from the last dose of their last antimyeloma therapy; and
Must have received at least 3 prior MM treatment regimens. and
Must have received a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody (eg, daratumumab); and
Should have failed treatment with or are intolerant to all established therapies
Subjects must have measurable disease, including at least one of the criteria below
M-protein quantities 0.5 g/dL by sPEP or
mg/24 hours urine collection by uPEP or
Serum FLC levels > 100 mg/L (milligrams/liter involved light chain) and an abnormal kappa/lambda (/) ratio in patients without detectable serum or urine M-protein or
For subjects with immunoglobulin class A (IgA) myeloma whose disease can only be reliably measured by quantitative immunoglobulin measurement, a serum IgA level 0.50 g/dL
Subject has an ECOG PS of 0-1
Subjects must have the following laboratory values (determined by local laboratory)
Absolute neutrophil count (ANC) 1.0 x 10^9/L
Platelets (plt) 75 x 10^9/L
Potassium within normal limits or correctable with supplements
Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) 2.5 x upper limit of normal (ULN)
Serum bilirubin 1.5 x ULN (or 2.0 x ULN for subjects with documented Gilbert's syndrome)
Estimated serum creatinine clearance of 60 mL/min
International normalized ratio (INR) < 1.5 x ULN and partial thromboplastin time (PTT) < 1.5 x ULN
Females of childbearing potential (FCBP) must
Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, at least two effective contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner), one of which must be barrier, from signing the ICF, throughout the study, during dose interruptions, and for up to 42 days following the last dose of CC-99712; and
Have two negative pregnancy tests as verified by the Investigator prior to starting CC-99712. Subject must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment. This applies even if the subject practices true abstinence from heterosexual contact. The subject may not receive IP until the Investigator has verified that the result of the pregnancy test is negative
a negative serum pregnancy test (sensitivity of at least 25 mIU/mL) at Screening
a negative serum or urine pregnancy test (Investigator's discretion) within 72 hours prior to Cycle 1 Day -1 of study treatment, and within 72 hours prior to Day -1 of every subsequent cycle (note that the Screening serum pregnancy test can be used as the test prior to Day -1 study treatment if it is performed within the prior 72 hours). A serum or urine pregnancy test (investigators discretion) must also be performed at the end of study for each FCBP
Avoid conceiving for 42 days after the last dose of CC-99712.7. Males must practice true abstinence (which must be reviewed on a monthly basis) or agree to use a condom (a latex condom is recommended) during sexual contact with a pregnant female or a FCBP and will avoid conceiving from signing the ICF, while participating in the study, during dose interruptions, and for at least 42 days following CC-99712 discontinuation, even if he has undergone a successful vasectomy
Subject is willing and able to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria

The presence of any of the following will exclude a subject from enrollment
In Part A only, subject has received prior investigational therapy directed at BCMA
Subject has symptomatic central nervous system involvement of MM
Subject has nonsecretory MM, plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis
Subjects with a history of class III or IV congestive heart failure (CHF) or severe non-ischemic cardiomyopathy, unstable angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months prior to signing ICF
Subject had a prior autologous stem cell transplant 3 months prior to starting CC-99712
Subject had a prior allogeneic stem cell transplant with either standard or reduced intensity conditioning 6 months prior to starting CC-99712 or is on systemic immunosuppression for graft-versus host disease
Subject had a prior chimeric antigen receptor T (CAR T) cell product 4 weeks prior to starting CC-99712
Subject had a prior systemic cancer-directed treatments or investigational modalities within 5 pharmacokinetic half-lives or 2 weeks prior to starting CC-99712, whichever is longer. The only exception is emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 mg/day for a maximum 4 days) before treatment
Subject had major surgery 2 weeks prior to starting CC-99712. Subjects must have recovered from any clinically significant effects of recent surgery
Subject is a pregnant or lactating female
Subject has known human immunodeficiency virus (HIV) infection
Subject has known history of chronic, active hepatitis B or C virus (HBV/HCV) infection
Subject requires ongoing treatment with chronic, therapeutic dosing of anti-coagulants (eg, warfarin, low molecular weight heparin, Factor Xa inhibitors)
Subject has a history of concurrent second cancers requiring active, ongoing systemic treatment
Subject has known history of cirrhosis or has clinically significant liver or biliary disease. Subjects with stable chronic liver or biliary disease (such as Gilbert's syndrome, asymptomatic gallstones, or hepatobiliary involvement of malignancy) may participate in the study, however, sponsor medical monitor must be contacted for a discussion before enrollment
Subject has a history of clinically significant corneal disease requiring therapy or ongoing active corneal disease
Subject has active peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note